Bryan Irving

Dr. Bryan Irving currently serves as the Chief Scientific Officer of Amunix. He has 30 years of experience in immunology, with nearly 20 years in industry focused on discovering and progressing immune drug candidates into the clinic for both autoimmune and oncology indications. Prior to joining Amunix, he served as Chief Scientific Officer of Five Prime Therapeutics, where he led research and preclinical drug development, and as Vice President of Cancer Immunology at CytomX Therapeutics, where he led immune applications of their protease-activatable, prodrug technology (included T cell bispecifics and T cell checkpoint targets). Prior to CytomX, he worked 12 years as a scientist at Genentech in the Departments of Immunology and Oncology/Cancer Immunology, where he was a key inventor and research leader for the PD-L1 immunotherapy atezolizumab (Tecentriq).

Dr. Irving received his Ph.D in Immunology from the University of California, San Francisco, and a B.A. in Physiology from the University of California, Berkeley. His doctoral work, performed in the laboratory of Dr. Arthur Weiss, pioneered the single-chain chimeric antigen receptor (CAR) technology. He performed post-doctoral work at Harvard and UCSF on early T cell development. His work has been published in top tier journals including Cell, Science, Cancer Cell, Nature Immunology, and Immunity, and he is an inventor on patents that include the single-chain CARs and atezolizumab. Dr Irving is also a musician and studied clarinet performance at the Eastman School of Music at the University of Rochester, NY.